NCT02386800 2026-03-16CINC424A2X01B Rollover ProtocolNovartisPhase 4 Active not recruiting279 enrolled
NCT04282187 2026-03-16Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsUniversity of WashingtonPhase 2 Recruiting25 enrolled
NCT07128381 2026-01-05Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer CenterPhase 1/2 Recruiting66 enrolled
NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT02158858 2025-10-08A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesConstellation PharmaceuticalsPhase 1/2 Completed336 enrolled
NCT04041050 2025-02-14A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmAbbViePhase 1 Active not recruiting85 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT02587598 2021-12-08Study of INCB053914 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated97 enrolled 40 charts
NCT01369498 2020-07-01Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia MyelofibrosisGilead SciencesPhase 2 Completed54 enrolled 16 charts
NCT01164163 2014-10-23INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative DiseaseChildren's Oncology GroupPhase 1 Completed49 enrolled